2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. JNK

JNK

c-Jun N-terminal kinase

JNK

Related Products

PDF 0.71 MB

JNK (c-Jun N-terminal kinase), a kinase subfamily belonging to the MAPK, is activated in response to various stress stimuli and possesses a wide variety of regulatory functions. The JNK family of serine/threonine protein kinases comprises three isoforms (JNK1, JNK2 and JNK3). JNKs are involved in the emergence and progression of diverse pathologies such as neurodegenerative, cardiovascular and metabolic disorders as well as inflammation and cancer.

Similar to the other MAP kinases, JNKs are activated by a phosphorylation cascade generally involving two types of upstream kinases, the so-called MAP kinase kinase kinases (MAP3K, MKKK) and the MAP kinase kinases (MAP2K; MKK). At the MAP2K level, JNKs are activated by MKK4 and MKK7, the former is a common activator of the JNK and the p38 MAP kinase signaling pathway. The JNK cascade shares various intersection points with other pathways making it a part of a complex signaling network.

JNK Isoform Specific Products:

JNK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-107596
    SR-3576
    		Inhibitor 98.2%
    SR-3576 is a highly potent and selective JNK3 inhibitor with an IC50 of 7 nM.
    SR-3576
  • HY-P1191
    JIP-1(153-163)
    		Inhibitor 99.42%
    JIP-1(153-163) (TI-JIP) is a peptide inhibitor of c-JNK, based on residues 153-163 of JNK-interacting protein-1 (JIP-1) (Modifications: Phe-11 = C-terminal amide).
    JIP-1(153-163)
  • HY-13022A
    CC-401
    		Inhibitor 98.60%
    CC-401 is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
    CC-401
  • HY-P2243
    D-JBD19
    		Control 99.84%
    D-JBD19 is a non-permeable peptide. D-JBD19 has neuroprotective effects.
    D-JBD19
  • HY-108646
    SX 011
    		Inhibitor 99.33%
    SX 011 is a p38 inhibitor with IC50s of 9 nM and 90 nM against p38α and p38β, respectively. SX 011 also inhibits JNK-2 with an IC50 of 100 nM. SX-011 is orally bioavailable.
    SX 011
  • HY-N7394A
    (-)-Zuonin A
    		Inhibitor 99.99%
    (-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively.
    (-)-Zuonin A
  • HY-B0239R
    Chloramphenicol (Standard)
    		Activator
    Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.
    Chloramphenicol (Standard)
  • HY-B1309
    Metacetamol
    		Activator
    Metacetamol (AMAP) is a non-hepatotoxic analog of acetaminophen (APAP). Metacetamol increases glutathione (GSH) in PHH and causes mitochondrial damage. Metacetamol increases total JNK in PHH cell .
    Metacetamol
  • HY-13319G
    JNK-IN-8 (GMP)
    		Inhibitor
    JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively.
    JNK-IN-8 (GMP)
  • HY-100233A
    IQ-1S
    		Inhibitor
    IQ-1S is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC50 of 1.8 μM. IQ-1 has binding affinity (Kd values) in the nanomolar range for all three JNKs with Kds of 87 nM, 360 nM, and 390 nM for JNK3, JNK2, and JNK1, respectively.
    IQ-1S
  • HY-P10140
    JNK-IN-15, Cell-Permeable
    		Inhibitor
    JNK-IN-15, Cell-Permeable (JNK inhibitor III) is an inhibitor of JNK. JNK-IN-15, Cell-Permeable can used in study age-related neurodegenerative diseasev.
    JNK-IN-15, Cell-Permeable
  • HY-14411
    JNK-1-IN-1
    		Inhibitor
    JNK-1-IN-1 is a JNK-1 inhibitor. JNK-1-IN-1 also inhibits MKK7 with an IC50 of 7.8μM. JNK-1-IN-1 bind to MKK7cp and acts as an inhibitor of JNK-1.
    JNK-1-IN-1
  • HY-N3711
    Dehydrocrenatine
    		Activator
    Dehydrocrenatidine, a β-carboline alkaloid that can be isolated from Picrasma quassioides. Dehydrocrenatidine induces cell apoptosis by activates ERK and JNK. Dehydrocrenatidine inhibits invasion and migration of cancer cells, it also suppresses neuronal excitability to exert analgesic effects.
    Dehydrocrenatine
  • HY-N3828
    epi-Eriocalyxin A
    		Inhibitor
    epi-Eriocalyxin A (Epieriocalyxin A), a diterpenoid isolated from Isodon eriocalyx, induces colon cancer apoptosis. epi-Eriocalyxin A also inhibits ERK1/2 and JNK activation, which suppresses Bcl-2 expression.
    epi-Eriocalyxin A
  • HY-161586
    Chloramphenicol/BSA
    		Activator
    Chloramphenicol/BSA is the antigen-adjuvant conjugate formed by the coupling of Chloramphenicol (HY-B0239) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Chloramphenicol/BSA
  • HY-149268
    JNK3 inhibitor-6
    		Inhibitor
    JNK3 inhibitor-6 (Compound A53) is a selective JNK3 Inhibitor (IC50=78 nM). JNK3 inhibitor-6 has neuroprotective effect, and can used for research of neurodegenerative diseases.
    JNK3 inhibitor-6
  • HY-150053
    JNK-IN-11
    		Inhibitor 98.01%
    JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC50 value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease.
    JNK-IN-11
  • HY-N6872R
    Actein (Standard)
    		Activator
    Actein (Standard) is the analytical standard of Actein. This product is intended for research and analytical applications. Actein, a triterpene glycoside, shows an inhibitory effect on cancer cells, which is isolated from the rhizomes of Cimicifuga foetida. Actein suppresses cell proliferation, induces autophagy and apoptosis through promoting ROS/JNK activation, and blunting AKT pathway in bladder cancer. Actein has little toxicity in vivo.
    Actein (Standard)
  • HY-RS08129
    Mapk9 Rat Pre-designed siRNA Set A
    		Inhibitor

    Mapk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mapk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Mapk9 Rat Pre-designed siRNA Set A
    Mapk9 Rat Pre-designed siRNA Set A
  • HY-169412
    MAPK-IN-3
    		Activator
    MAPK-IN-3 (Compound 4a) is an anti-proliferative agent that shows particularly strong inhibitory effects on KYSE 30, HCT 116, and HGC 27, with IC50 values of 0.57 μM, 3.27 μM, and 2.28 μM, respectively. MAPK-IN-3 blocks the cell cycle via a p53-dependent mechanism and induces cell apoptosis through a p53-independent mechanism. MAPK-IN-3 downregulates the expression of cell cycle-related proteins like Cyclin D1 and cyclin B1, upregulates pro-apoptotic proteins such as cleaved PARP, cleaved caspase-7, and cleaved caspase-9, and reduces the expression of anti-apoptotic proteins like Bcl-2. Additionally, MAPK-IN-3 increases the intracellular level of ROS in KYSE 30 cells and upregulates the expression of members of the MAPK signaling pathway associated with ROS, such as p-ERK, p-p38 and p-JNK.
    MAPK-IN-3
Cat. No. Product Name / Synonyms Application Reactivity
JNK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.